Your session is about to expire
← Back to Search
IAG933 for Mesothelioma
Study Summary
This trial is testing a new drug to see if it is safe and effective in treating mesothelioma, tumors with NF2/LATS1/LATS2 mutations, and tumors with YAP/TAZ fusion.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have advanced mesothelioma and standard treatments haven't worked or aren't suitable for me.I have an advanced solid tumor with an NF2 mutation and can't use standard treatments.I have an advanced cancer that cannot be surgically removed.My bone marrow is not working well.I can have a biopsy according to my hospital's rules.I am willing to have tumor biopsies before and during the study.I have had a serious lung condition from medication or other causes.Standard treatments have not worked for me, or I cannot take them.I have an advanced solid tumor with YAP/TAZ fusion or EHE confirmed by tests, and standard treatments haven't worked for me.My tumor has specific genetic changes not related to mesothelioma.My kidneys are not working well.I have mesothelioma and haven't used treatments like Optune Lua in the last 2 weeks.My liver is not working properly.I have heart problems or risk factors for heart disease.I currently have an active COVID-19 infection.You have certain lab results that are higher than a specific level.I haven't taken any cancer treatments recently.I have never been treated with a TEAD inhibitor.I do not have any other cancer besides the one being treated in this study.I am 18 years old or older.My cancer diagnosis was confirmed through tissue examination.I have advanced MPM and standard treatments haven't worked or I can't receive them.You have at least one specific type of detectable abnormality in your body according to certain guidelines.
- Group 1: Group 1
- Group 2: Group 4
- Group 3: Group 2
- Group 4: Group 3
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is admission to this experiment available for participants currently?
"Affirmative. Clinicaltrials.gov confirms that the initial posting of this medical study was on October 21st 2021 and has been actively seeking candidates since, with its most recent edit occuring November 17th 2022. This trial is looking to enrol 156 individuals at 5 sites across the country."
What are the expected outcomes of this experiment?
"The primary purpose of this study, which is expected to last 3 years, will be assessing the number of patients with adverse and serious adverse events. Secondary aims include calculating the duration of response (DOR) as per RECIST v1.1/mRECIST v1.1 (for malignant pleural mesothelioma), characterizing the pharmacokinetics of IAG933 through accumulation ratio (Racc - dose escalation only), and measuring disease control rate (DCR) according to RECIST v1.1/ mRECIST v 1."
Does IAG933 present any risks to those taking it medicinally?
"The safety of IAG933, based on the limited evidence from Phase 1 trials, has been estimated to be a 1."
What are the geographical areas in which this experiment is operational?
"Presently, this trial is operational in 5 locations across the United States and Canada. Sites are hosted in cities such as Boston, Montreal, and Houston. Individuals looking to participate should select a local centre to avoid unnecessary travel costs."
What is the participant capacity for this research initiative?
"Novartis Pharmaceuticals is responsible for the execution of this trial, which necessitates 156 qualifying patients. The study will be conducted out of Massachusetts General Hospital in Boston and a Novartis Investigative Site located in Montreal, Quebec."
Share this study with friends
Copy Link
Messenger